Centro de Investigación de Medicina Aplicada (CIMA)
Centro / Instituto vinculado a la Universidad de Navarra
![Foto de Centro de Investigación de Medicina Aplicada (CIMA)](/img/uploaded/775F334D27340F135DFC5AC46D7B50CB.jpg)
![Foto de Memorial Sloan Kettering Cancer Center](/img/noimage_org.png)
Memorial Sloan Kettering Cancer Center
Nueva York, Estados UnidosPublicaciones en colaboración con investigadores/as de Memorial Sloan Kettering Cancer Center (71)
2024
-
A road map for the treatment of pediatric diffuse midline glioma
Cancer Cell
-
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials
Nature Communications, Vol. 15, Núm. 1
-
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors
Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 3
-
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216
-
Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma
Blood cancer discovery, Vol. 5, Núm. 3, pp. 146-152
-
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease
Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 4
2023
-
Cancer Cell-Intrinsic Alterations Associated with an Immunosuppressive Tumor Microenvironment and Resistance to Immunotherapy in Lung Cancer
Cancers, Vol. 15, Núm. 12
-
Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Cancer Discovery, Vol. 13, Núm. 11, pp. 2370-2393
-
Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)
Leukemia
-
IASLC Lung Cancer Staging Project: The New Database to Inform Revisions in the Ninth Edition of the TNM Classification of Lung Cancer
Journal of Thoracic Oncology, Vol. 18, Núm. 5, pp. 564-575
-
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022
Annals of Oncology, Vol. 34, Núm. 1, pp. 48-60
-
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial
Nature Medicine, Vol. 29, Núm. 6, pp. 1370-1378
2022
-
BACH2 restricts NK cell maturation and function, limiting immunity to cancer metastasis
Journal of Experimental Medicine, Vol. 219, Núm. 12
-
Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma patients using a novel cfDNA algorithm for treatment with RLY-4008, a highly selective irreversible FGFR2 inhibitor
European Journal of Cancer, Vol. 174, pp. S116
-
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies
Blood cancer journal, Vol. 12, Núm. 2, pp. 32
-
Lactobacillus supports Clostridiales to restrict gut colonization by multidrug-resistant Enterobacteriaceae
Nature Communications, Vol. 13, Núm. 1
-
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
The Lancet Oncology, Vol. 23, Núm. 1, pp. 77-90
-
The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: Unresolved Issues to be Addressed for the Next Ninth Edition of the TNM Classification of Malignant Tumors
Journal of Thoracic Oncology, Vol. 17, Núm. 6, pp. 838-851
2021
-
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials
Leukemia, Vol. 35, Núm. 1, pp. 18-30
-
Minimal residual disease in Myeloma: Application for clinical care and new drug registration
Clinical Cancer Research, Vol. 27, Núm. 19, pp. 5195-5212